Table 2.
Summary of recommended prevention depending on mutations detected and menopausal status
| Mutated gene | Menopausal status | Surgery, % | Intensive screening, % | Abstain, % |
|---|---|---|---|---|
| BRCA1 | Pre | 67 | 14 | 20 |
| BRCA1 | Post | 61 | 17 | 23 |
| BRCA2 | Pre | 64 | 14 | 22 |
| BRCA2 | Post | 42 | 32 | 26 |
| PALB2 | Pre | 42 | 32 | 26 |
| PALB2 | Post | 20 | 53 | 27 |
| ATM | Pre | 9 | 73 | 18 |
| ATM | Post | 1.5 | 79 | 20 |
| CHEK2 | Pre | 8 | 71 | 21 |
| CHEK2 | Post | 1.5 | 79 | 20 |